Certican, known generically as everolimus, is a medication primarily used in the field of organ transplantation to prevent the body from rejecting the new organ. It belongs to a class of drugs known as mTOR inhibitors, which work by suppressing the immune system to reduce the risk of rejection. Certican is specifically designed for use in patients who have received a kidney or liver transplant, and it is often used in combination with other immunosuppressive medications to optimize patient outcomes. By inhibiting the activity of the mammalian target of rapamycin (mTOR), Certican effectively reduces the proliferation of T cells and B cells, which are involved in the immune response that can lead to organ rejection. Its use is critical in the post-transplantation care plan to ensure the longevity of the transplanted organ and to maintain the overall health of the recipient.